The application for the long-acting HIV therapy by Gilead (GILD.US) is about to be submitted.
Gilead Sciences (GILD.US) today announced the full results of the second pivotal Phase 3 trial PURPOSE 2 for lenacapavir, an investigational long-acting HIV-1 capsid inhibitor administered once every six months for HIV prevention.
Wolfe Research Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $110
Gilead, Vertex Initiated as New Big Biotech Buys at Citi
Gilead Sciences, Inc. (GILD) Is Attracting Investor Attention: Here Is What You Should Know
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Today's Analyst Rating | NVIDIA Price Target Raised to $175 by Oppenheimer, Amazon Price Target Raised to $250 by Needham
Nov 14, Wall Street analysts have updated their stock ratings today including $NVIDIA(NVDA.US)$ and $Amazon(AMZN.US)$.